Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07152002 | A Study of LY4064912 in Healthy Participants and With Overweight or Obesity | PHASE1 | RECRUITING | 144 | — | — | Aug 28, 2025 | Nov 1, 2026 | Apr 20, 2026 | 3 | United States, Singapore |
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY4064912 (Cohorts 1-6) | EXPERIMENTAL | LY4064912 administered subcutaneously (SC) |
| Part A: LY4064912 (Cohort 6a) | EXPERIMENTAL | LY4064912 administered intravenously (IV) |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo administered SC and IV |
| Part B: LY4064912 (Cohorts 7-10) | EXPERIMENTAL | LY4064912 administered SC |
| Part B: Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Part C: LY4064912 (Cohort 11) | EXPERIMENTAL | LY4064912 administered SC |
| Part C: Placebo | EXPERIMENTAL | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY4064912 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Age is 21-65 years old at Singapore Sites * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring Part A: Body Mass Index (BMI) within the range greater than or equal ...